Porownywarka

PTD-DBM vs GHK-Cu side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

PTD-DBMGHK-Cu

Udostępnij porównanie peptydów

Wlasciwosc	PTD-DBM	GHK-Cu
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical - animal (mouse) studies only, no human trials Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Hair loss and hair regrowth research (androgenetic alopecia)	Skin rejuvenation, wound healing, hair growth, anti-aging
Jak dziala	PTD-DBM combines a protein-transduction domain with a motif that binds Dishevelled. The supplied source reports that this can disrupt CXXC5 association with Dishevelled, increasing Wnt/beta-catenin pathway activity in cell and mouse models. It further reports that valproic acid, described as a GSK-3beta inhibitor, was studied alongside PTD-DBM and produced more activity in the reported model than either component alone. Human validation is not supplied.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typowe dawkowanie	Sold as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study · Once daily to the scalp in most community routines	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Dawkowanie z badań	~6 mg/mL PTD-DBM + ~72 mg/mL valproic acid, topical (study reported these as 2 mM and 500 mM) · Applied over several weeks in animal studies · Topical (applied to skin) in published research; usually co-applied with valproic acid	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typowy czas trwania	Applied over several weeks in animal studies	Varies by application
Podanie	Topical (applied to skin) in published research; usually co-applied with valproic acid	Subcutaneous injection or topical application
Timing	Not established (topical in animal studies) With or without food	Evening for skin or recovery contexts With or without food
Poziom dowodów	Przedkliniczne	Badania kliniczne
Mozliwe skutki uboczne	No human safety data are available in the supplied evidence. (Human adverse effects have not been characterized.) Possible local skin irritation, with valproic acid identified as a potential contributor. (Reported as a possibility rather than a documented human safety finding.) Theoretical concern regarding prolonged Wnt/beta-catenin activation and tumor biology. (Long-term implications are unstudied.) +2 więcej Systemic absorption and longer-term safety are unknown. (No human exposure data are supplied.) Effects in humans remain unproven. (Individual human response patterns cannot be established from this evidence.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Podsumowanie researchu	The supplied record attributes the principal work to Lee SH and colleagues in the Choi laboratory at Yonsei University, published in the Journal of Investigative Dermatology in 2017. It describes topical mouse experiments in which PTD-DBM was associated with earlier anagen after shaving and with follicle formation in wounded skin. The source reports solutions of 2 mM PTD-DBM and 500 mM valproic acid, approximately 6 mg/mL and 72 mg/mL respectively, and says this combination performed better than roughly 2 % minoxidil (reported as 100 mM) in that mouse model. It also notes 2024–2025 reviews discussing the compound and its CXXC5-related rationale. No completed peer-reviewed human efficacy study is supplied as of 2026; human pharmacokinetics, safety, dosing, and real-world effects remain unknown, and the source reports no FDA approval or IND on record.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
Referencje	Źródło Źródło +1 więcej Źródło	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

PTD-DBM

GHK-Cu

Kategoria

Skóra i włosy

Znany tez jako

CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical - animal (mouse) studies only, no human trials

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Hair loss and hair regrowth research (androgenetic alopecia)

Skin rejuvenation, wound healing, hair growth, anti-aging

Jak dziala

PTD-DBM combines a protein-transduction domain with a motif that binds Dishevelled. The supplied source reports that this can disrupt CXXC5 association with Dishevelled, increasing Wnt/beta-catenin pathway activity in cell and mouse models. It further reports that valproic acid, described as a GSK-3beta inhibitor, was studied alongside PTD-DBM and produced more activity in the reported model than either component alone. Human validation is not supplied.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typowe dawkowanie

Sold as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study · Once daily to the scalp in most community routines

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Dawkowanie z badań

~6 mg/mL PTD-DBM + ~72 mg/mL valproic acid, topical (study reported these as 2 mM and 500 mM) · Applied over several weeks in animal studies · Topical (applied to skin) in published research; usually co-applied with valproic acid

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typowy czas trwania

Applied over several weeks in animal studies

Varies by application

Podanie

Topical (applied to skin) in published research; usually co-applied with valproic acid

Subcutaneous injection or topical application

Timing

Not established (topical in animal studies)

With or without food

Evening for skin or recovery contexts

With or without food

Poziom dowodów

Przedkliniczne

Badania kliniczne

Mozliwe skutki uboczne

No human safety data are available in the supplied evidence. (Human adverse effects have not been characterized.)
Possible local skin irritation, with valproic acid identified as a potential contributor. (Reported as a possibility rather than a documented human safety finding.)
Theoretical concern regarding prolonged Wnt/beta-catenin activation and tumor biology. (Long-term implications are unstudied.)

+2 więcej

Systemic absorption and longer-term safety are unknown. (No human exposure data are supplied.)
Effects in humans remain unproven. (Individual human response patterns cannot be established from this evidence.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Podsumowanie researchu

The supplied record attributes the principal work to Lee SH and colleagues in the Choi laboratory at Yonsei University, published in the Journal of Investigative Dermatology in 2017. It describes topical mouse experiments in which PTD-DBM was associated with earlier anagen after shaving and with follicle formation in wounded skin. The source reports solutions of 2 mM PTD-DBM and 500 mM valproic acid, approximately 6 mg/mL and 72 mg/mL respectively, and says this combination performed better than roughly 2 % minoxidil (reported as 100 mM) in that mouse model. It also notes 2024–2025 reviews discussing the compound and its CXXC5-related rationale. No completed peer-reviewed human efficacy study is supplied as of 2026; human pharmacokinetics, safety, dosing, and real-world effects remain unknown, and the source reports no FDA approval or IND on record.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

Referencje

+1 więcej

+1 więcej

Pełny profil